GSK's Witty boasts about looming R&D success

Even Andrew Witty's dinnertime conversation can make the news. The Independent quotes table side sources who heard the GSK ($GSK) CEO vowing to wow the financial world with the company's R&D performance by the end of next year. "He said in a little over a year we would see just what is in their R&D [research and development] portfolio. He was quite vocal that GSK would be protecting margins." There's no word on what he thought about the food. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.